All In Biotech

Drug Trial Radar · NCT00379769

RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes

A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and Glycaemia

Last checked: Nov 19, 2026Latest source record: Mar 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,447 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,447

Actual

Start

Apr 2001

Primary completion

Dec 2008

Study completion Dec 2008

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 22, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background glucose lowering therapy. Patients inadequately controlled on background metformin will be randomised to receive, in addition to metformin, either rosiglitazone or a sulfonylurea(glibenclamide, gliclazide or glimepiride) in a ratio of 1:1. Patients inadequately controlled on background SU will be randomised to receive, in addition to SU, either rosiglitazone or metformin in a ratio of 1:1. Equal numbers of patients receiving background metformin and SU at entry will be entered into the study.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • RosiglitazoneDrug

    Rosiglitazone maximum 8 mg per day

  • SulfonylureaDrug

    Sulfonylurea (SU) maximum permitted daily dose

  • MetforminDrug

    Metformin maximum permitted daily dose .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation EventsTime frame: Baseline through End of Study (up to 7.5 years)
  2. Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any CauseTime frame: Baseline through End of Study (up to 7.5 years)
  3. Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
  4. Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
  5. Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
  6. Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
  7. Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
  8. Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
  9. Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
  10. Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)

Locations

446 sites in 25 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Miranda, New South Wales, Australia

  • GSK Investigational Site

    Randwick, New South Wales, Australia

  • GSK Investigational Site

    Wollongong, New South Wales, Australia

  • GSK Investigational Site

    Carina Heights, Queensland, Australia

  • GSK Investigational Site

    Kippa-Ring, Queensland, Australia

  • GSK Investigational Site

    Sherwood, Queensland, Australia

  • GSK Investigational Site

    Keswick, South Australia, Australia

  • GSK Investigational Site

    North Adelaide, South Australia, Australia

  • GSK Investigational Site

    Port Lincoln, South Australia, Australia

  • GSK Investigational Site

    Heidelberg, Victoria, Australia

  • GSK Investigational Site

    Malvern, Victoria, Australia

  • GSK Investigational Site

    Antwerp, Belgium

  • GSK Investigational Site

    Arlon, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Genk, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Kortrijk, Belgium

  • GSK Investigational Site

    Liège, Belgium

  • GSK Investigational Site

    Moerkerke, Belgium

  • GSK Investigational Site

    Oostham, Belgium

  • GSK Investigational Site

    Roeselare, Belgium

  • GSK Investigational Site

    Sint-Gillis-Waas, Belgium

  • GSK Investigational Site

    Vilvoorde, Belgium

  • GSK Investigational Site

    Pleven, Bulgaria

  • GSK Investigational Site

    Plovdiv, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Varna, Bulgaria

  • GSK Investigational Site

    Krapinske Toplice, Croatia

  • GSK Investigational Site

    Rijeka, Croatia

  • GSK Investigational Site

    Slavonski Brod, Croatia

  • GSK Investigational Site

    Varaždin, Croatia

  • GSK Investigational Site

    Zagreb, Croatia

  • GSK Investigational Site

    Brno, Czechia

  • GSK Investigational Site

    České Budějovice, Czechia

  • GSK Investigational Site

    Holice V Cechach, Czechia

Showing 40 of 446 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.